D
David L. Brown
Researcher at Scott & White Hospital
Publications - 17
Citations - 7864
David L. Brown is an academic researcher from Scott & White Hospital. The author has contributed to research in topics: Valve replacement & Aortic valve replacement. The author has an hindex of 10, co-authored 16 publications receiving 5415 citations.
Papers
More filters
Journal ArticleDOI
Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients.
Martin B. Leon,Craig R. Smith,Michael J. Mack,Michael J. Mack,Rajendra Makkar,Lars G. Svensson,Susheel Kodali,Vinod H. Thourani,Murat Tuzcu,D. Craig Miller,Howard C. Herrmann,Darshan Doshi,David J. Cohen,Augusto D. Pichard,Samir R. Kapadia,Todd M. Dewey,Vasilis Babaliaros,Wilson Y. Szeto,Mathew R. Williams,Dean J. Kereiakes,Alan Zajarias,Kevin L. Greason,Brian Whisenant,Robert W. Hodson,Jeffrey W. Moses,Alfredo Trento,David L. Brown,William F. Fearon,Philippe Pibarot,Rebecca T. Hahn,Wael A. Jaber,William N. Anderson,Maria Alu,John G. Webb +33 more
TL;DR: In intermediate-risk patients, TAVR was similar to surgical aortic-valve replacement with respect to the primary end point of death or disabling stroke; surgery resulted in fewer major vascular complications and less paravalvular aorta regurgitation.
Journal ArticleDOI
Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients
Michael J. Mack,Martin B. Leon,Vinod H. Thourani,Raj Makkar,Susheel Kodali,Mark J. Russo,Samir R. Kapadia,S. Chris Malaisrie,David J. Cohen,Philippe Pibarot,Jonathon Leipsic,Rebecca T. Hahn,Philipp Blanke,Mathew R. Williams,James M. McCabe,David L. Brown,Vasilis Babaliaros,Scott M. Goldman,Wilson Y. Szeto,Philippe Généreux,Ashish Pershad,Stuart J. Pocock,Maria Alu,John G. Webb,Craig R. Smith +24 more
TL;DR: Among patients with severe aortic stenosis who were at low surgical risk, the rate of the composite of death, stroke, or rehospitalization at 1 year was significantly lower with TAVR than with surgery.
Journal ArticleDOI
Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement.
Raj Makkar,Vinod H. Thourani,Michael J. Mack,Susheel Kodali,Samir R. Kapadia,John G. Webb,Sung-Han Yoon,Alfredo Trento,Lars G. Svensson,Howard C. Herrmann,Wilson Y. Szeto,D. Craig Miller,Lowell P. Satler,David J. Cohen,Todd M. Dewey,Vasilis Babaliaros,Mathew R. Williams,Dean J. Kereiakes,Alan Zajarias,Kevin L. Greason,Brian Whisenant,Robert W. Hodson,David L. Brown,William F. Fearon,Mark J. Russo,Philippe Pibarot,Rebecca T. Hahn,Wael A. Jaber,Erin Rogers,Ke Xu,Jaime Wheeler,Maria Alu,Craig R. Smith,Martin B. Leon +33 more
TL;DR: There was no significant difference in the incidence of death or disabling stroke at 5 years after TAVR as compared with surgical aortic-valve replacement among patients with severe, symptomaticAortic stenosis who were at intermediate surgical risk.
Journal ArticleDOI
Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Valves: PARTNER 3 Cardiac Computed Tomography Substudy
Raj Makkar,Philipp Blanke,Jonathon Leipsic,Vinod H. Thourani,Tarun Chakravarty,David L. Brown,Alfredo Trento,Robert A. Guyton,Vasilis Babaliaros,Mathew R. Williams,Hasan Jilaihawi,Susheel Kodali,Isaac George,Michael T. Lu,James M. McCabe,John D. Friedman,Richard W. Smalling,Shing Chiu Wong,Shahram Yazdani,Deepak L. Bhatt,Jeroen J. Bax,Samir R. Kapadia,Howard C. Herrmann,Michael J. Mack,Martin B. Leon +24 more
TL;DR: Subclinical leaflet thrombosis was more frequent in transcatheter compared with surgical valves at 30 days, but not at 1 year, and the impact of HALT on thromboembolic complications and structural valve degeneration needs further assessment.
Journal ArticleDOI
Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk.
Martin B. Leon,Michael J. Mack,Rebecca T. Hahn,Vinod H. Thourani,Raj Makkar,Susheel Kodali,Maria Alu,Mahesh V. Madhavan,Katherine H. Chau,Mark J. Russo,Samir R. Kapadia,S. Chris Malaisrie,David J. Cohen,Philipp Blanke,Jonathon Leipsic,Mathew R. Williams,James M. McCabe,David L. Brown,Vasilis Babaliaros,Scott M. Goldman,Howard C. Herrmann,Wilson Y. Szeto,Philippe Généreux,Ashish Pershad,Michael T. Lu,John G. Webb,Craig R. Smith,Philippe Pibarot,Partner Investigators +28 more
TL;DR: The safety and effectiveness of transcatheter aortic valve replacement (TAVR) versus surgery for the primary endpoint of death, stroke, or rehospitalization at 1 year was evaluated in the PARTNER 3 trial as discussed by the authors.